MINT-EPLERENONE
As listed in the register: MINT-EPLERENONE
50 mg · tablet
- Prescription only
- Heart, blood pressure and circulation
- Active substance
- Eplerenone
- Made by
- Mint Pharmaceuticals Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (eplerenone). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS).
Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium.
Metabolism and Excretion Eplerenone metabolism is primarily mediated via CYP3A4.
Following a single oral dose of radiolabeled drug, approximately 32% of the dose was excreted in the feces and approximately 67% was excreted in the urine.
Absorption is not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-06-23
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (eplerenone). It describes the substance, not this Bulgarian product — its uses and doses can differ.
- For All Patients INSPRA is contraindicated in all patients with:. serum potassium >5.5 mEq/L at initiation,. creatinine clearance ≤30 mL/min, or. concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1), Clinical Pharmacology (12.3) ].
- Serum potassium >5.5 mEq/L at initiation ( 4 ).
- Creatinine clearance ≤30 mL/min ( 4 ).
- Concomitant use with strong CYP3A inhibitors ( 4, 7.1 ) For the treatment of hypertension:.
Most common adverse reactions (>2% and more frequent than with placebo): hyperkalemia and increased creatinine.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States9 matching products
Bulgaria5 matching products
Spain25 matching products
- INSPRA 50 mg eplerenona · comprimido recubierto con película2 makers
- ELECOR 50 mg eplerenona · comprimido recubierto con película
- EPLERENONA ALTER 50 mg · comprimido recubierto con película
- EPLERENONA ARISTO 50 mg · comprimido recubierto con película
- EPLERENONA AUROVITAS SPAIN 50 MG · comprimido recubierto con película
- EPLERENONA BLUEFISH 50 mg · comprimido recubierto con película
- EPLERENONA CINFA 50 MG · comprimido recubierto con película
- EPLERENONA CINFAMED 50 mg · comprimido recubierto con película
Netherlands11 matching products
- Eplerenon Accord 50 mg filmomhulde tabletten 50 mg · filmomhulde tablet
- Eplerenon Amarox 50 mg 50 mg · filmomhulde tablet
- Eplerenon Aurobindo 50 mg 50 mg · filmomhulde tablet
- Eplerenon Krka 50 mg filmomhulde tabletten 50 mg · filmomhulde tablet
- Eplerenon Mylan 50 mg 50 mg · filmomhulde tablet
- Eplerenon Sandoz 50 mg 50 mg · filmomhulde tablet
- Eplerenon Synthon 50 mg 50 mg · filmomhulde tablet
- Eplerenon Teva 50 mg 50 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Mint Pharmaceuticals Inc |
|---|---|
| Active substance | Eplerenone |
| Used in | Heart, blood pressure and circulation |
| Strength | 50 mg |
| Form | tablet |
| Classification | C03DA04 · Heart, blood pressure and circulation |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02471450 |
| DPD drug code | 96056 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 25 mg
- 50 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.